Working… Menu

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma (ROCK - CACG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02152774
Recruitment Status : Unknown
Verified April 2015 by Jessica Jasien, New York Glaucoma Research Institute.
Recruitment status was:  Active, not recruiting
First Posted : June 2, 2014
Last Update Posted : April 24, 2015
Information provided by (Responsible Party):
Jessica Jasien, New York Glaucoma Research Institute

No Study Results Posted on for this Study
Recruitment Status : Unknown
Actual Primary Completion Date : February 2015
Study Completion Date : No date given